For women who have lived with PCOS, the diagnosis has not disappeared. The name is changing because the science, and the language used to describe it, have slowly caught up with the condition.
‘Polycystic ovary syndrome’ put the spotlight on cysts and ovaries. But the ovarian features previously described are actually small follicles, not cysts in the usual clinical sense, and they do not need repeated checking or monitoring simply because of the diagnosis.
The condition also reaches well beyond the ovaries. PMOS recognises the endocrine, metabolic and ovarian features of the syndrome, and the wide variation in how it presents.
PCOS/PMOS can affect menstrual cycles, ovulation, fertility, skin, hair growth, weight, insulin regulation, cardiometabolic risk, psychological wellbeing and sense of self. For some women, it starts with irregular periods or acne. For others, it becomes visible during fertility investigations, weight changes, insulin resistance, or concerns about longer-term health.
The old name may have contributed to a narrow focus on the ovaries. Many women have experienced long delays in diagnosis, fragmented care, or advice that does not connect the reproductive, metabolic, skin, emotional and longer-term health aspects of the condition.
A clearer name may help health practitioners see what women have long known – this is a whole-body condition that can be difficult across the life course. It may also support more effective care by helping clinicians connect the different features of the condition, rather than treating each symptom in isolation.
The name change follows a large international consensus process involving people with lived experience, health professionals, researchers and patient organisations. The goal was not simply to replace one label with another, but to choose language that is more accurate, less narrowly reproductive, and easier to use across clinical care, research, education and health systems.
Both terms will probably coexist for a while. Many women will still recognise PCOS, and many will continue to feel connected to that name and the community built around it. PMOS does not erase that history. It gives clinicians, researchers and health systems a more accurate way to describe the condition women are actually living with.
References:
Reference: Teede, H. J., M. B. Khomami, R. Morman, J. S. Laven, A. E. Joham, M. F. Costello, M. Patil, D. A. Rees, L. Berry and M. G. Cree (2026). “Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.” The Lancet.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext